January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
15 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” 5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.
November 2021 in “World Family Medicine Journal /Middle East Journal of Family Medicine” Inclisiran is effective at lowering cholesterol.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
13 citations
,
January 2015 in “Steroids” The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
30 citations
,
October 2020 in “Nature Communications” Finasteride irreversibly affects human steroid 5α-reductase 2, providing insight into its catalytic mechanism and disease-related mutations.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.
1 citations
,
January 1995 in “Journal of Investigative Dermatology” RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
47 citations
,
June 2009 in “Journal of Biological Chemistry” Finasteride helps treat hair loss and prostate enlargement by blocking a specific enzyme.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
January 2004 in “Pharmaceutical biotechnology” Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
June 2021 in “F1000Research” Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
48 citations
,
February 2006 in “Molecular and Cellular Endocrinology” 5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
3 citations
,
December 2018 in “Biomedical and pharmacology journal/Biomedical & pharmacology journal” Compound 3 protects the heart from damage by activating A1-adenosine receptors.
January 2019 in “Urology Practice” Urologists prescribe newer medications more often than primary care physicians, who could benefit from more education on treatment options.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
13 citations
,
December 2017 in “Archives of Medical Sciences” Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.
72 citations
,
January 2011 in “Current Pharmaceutical Design” S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
August 2024 in “Latin American Journal of Development” 5α-reductase enzymes are crucial in certain disorders, and while treatment advances exist, more research on SRD5A3 is needed.